Quell Therapeutics is based on GL’s work on a population of cells that has been studied in her laboratory and then translated to the clinic to prevent transplant rejections. The aim of Quell is to cure inflammatory diseases including autoimmune and inflammatory diseases and organ transplantation.

Company: King's College London (KCL)